RECRUITING

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Talk to us

Conditions

Solid Tumor, Adult

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.

Official Title

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies

Quick Facts

Study Start:2019-10-25
Study Completion:2025-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04092673

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Mark Densel
CONTACT
858-925-8215
clinicaltrials@effector.com

Principal Investigator

Douglas Warner, MD
STUDY_DIRECTOR
EFFECTOR Therapeutics, Inc.

Study Locations (Sites)

University of Southern California
Los Angeles, California, 90033
United States
Valkyrie Clinical Trials
Los Angeles, California, 90067
United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663
United States
Stanford University
Palo Alto, California, 94304
United States
START Midwest
Grand Rapids, Michigan, 49546
United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169
United States
Memorial Sloan Kettering Cancer Center- Monmouth
Middletown, New Jersey, 07748
United States
Memorial Sloan Kettering Cancer Center- Commack
Commack, New York, 11725
United States
Memorial Sloan Kettering Cancer Center- Westchester
Harrison, New York, 10604
United States
Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care
New York, New York, 11101
United States
University of Toledo Medical Center
Toledo, Ohio, 43614
United States
MD Anderson Cancer Center
Houston, Texas, 77030
United States
New Experimental Therapeutics of San Antonio - NEXT Oncology
San Antonio, Texas, 78229
United States
Virginia Cancer Specialists
Fairfax, Virginia, 22031
United States

Collaborators and Investigators

Sponsor: Effector Therapeutics

  • Douglas Warner, MD, STUDY_DIRECTOR, EFFECTOR Therapeutics, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-10-25
Study Completion Date2025-03-31

Study Record Updates

Study Start Date2019-10-25
Study Completion Date2025-03-31

Terms related to this study

Additional Relevant MeSH Terms

  • Solid Tumor, Adult